TP53 and neuroblastoma: In this study, we have demonstrated that treatment with ceritinib in combination with CGM097 synergistically inhibits the proliferation of ALK-mutated and TP53 wild-type neuroblastoma cell lines in vitro and results in a shrinkage of tumor volumes below palpable detection in vivo, providing evidence for the effectiveness of combined inhibition of ALK and MDM2.